vVardis Raises $175 Million Ahead of NYSE IPO: NYSE Content Update
NYSE issues a pre-market daily advisory direct from the trading floor.
NEW YORK, Nov. 13, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins.
Kristen Scholer delivers the pre-market update on November 13th
- vVARDIS will list on the NYSE under the ticker symbol VVVV
- The dental health firm priced 9.72 million shares at $18 apiece.
- vVARDIS (NYSE: VVVV) says that it provides the first commercially available peptide-containing formulation to treat early cavities without drilling.
- Co-founders, Co-Chairs and Co-CEOs Dr. Haley Abivardi and Dr. Goly Abivardi will join NYSE Live to discuss their decision to take the company public.
- VAST Data announces it has received more than $10 billion in commitments
- The AI operating system says the funds came from 14 of the more than 1,000 companies it serves.
- The $10 billion will be deployed toward its software and supporting platform.
- VAST Founder + CEO Renan Hallak will join NYSE Live to discuss how the company's AI OS has become the platform of choice for AI cloud operators.
- Kraft Heinz looks to build off Thursday's momentum at the NYSE
- The food and beverage giant was on hand to celebrate its recent NYSE listing.
- Senior leaders outlined the firm's plan for sustainable, profitable growth at its investor day.
- Shares of Kraft Heinz (NYSE: KHC) rose by 0.9% during Thursday's session.
Opening Bell
vVardis (NYSE: VVVV) celebrate their IPO on the New York Stock Exchange
Closing Bell
Revvity (NYSE: RVTY) celebrates its 2026 Investor Day
For market insights, IPO activity, and today's opening bell, download the NYSE TV App and check out the NYSE YouTube: TV.NYSE.com and YouTube.com/@NYSEofficial
View original content to download multimedia:https://www.prnewswire.com/news-releases/vvardis-raises-175-million-ahead-of-nyse-ipo-nyse-content-update-302938983.html
This press release may not be republished, redistributed, resold or sublicensed without the prior written approval of PR Newswire.
AlphAI analysis
Written by AlphAI from the release above, not by the issuer or PR Newswire. Informational, not investment advice.
The 30-second read
Why it matters
The disclosed IPO details provide traders with a concrete entry point and set expectations for initial trading dynamics.
Market read
First‑report of a $175 M IPO adds a new tradable security and may attract IPO‑focused investors.
What to watch
Potential regulatory scrutiny of the peptide formulation and competition from established oral‑care brands.
Background
The article is a PR release announcing vVARDIS's upcoming NYSE listing, share pricing, and capital raise.
Ticker impact
vVARDIS announced a $175 million capital raise and pricing of 9.72 million shares at $18 ahead of its NYSE IPO under ticker VVVV.
likely upward pressure as investors allocate to the newly priced offering
First‑report of a sizable $175 M raise and confirmed share price creates a clear entry point for traders.
Market effects
Adds a new public player to the dental health and oral‑care sector, potentially increasing sector coverage.
Boosts NYSE IPO pipeline activity in the US market.
Limited to US equity markets; no immediate global macro effect.
Counterpoint
If demand for dental‑health IPOs wanes, the stock could face weak aftermarket performance despite the raise.
Key entities
- companyvVARDIS
Dental health firm launching an IPO on NYSE.